Wed 01/05/2022 12:24 PM
Aenova continued underperforming in October, as weak sales in its Solids business unit left the German contract manufacturer for the pharmaceutical industry trailing both its budget and prior-year results. The group broke even in terms of free cash flow but net leverage continued to creep up, sources told Reorg.
Sales came in at €59 million in October, which was 10.7% below the prior-year result and 14.8% behind budget. On a year-to-date basis, sales reached €582 million, which was 6.8%
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2022 Reorg Research, Inc. All rights reserved.